Jordan E. Axelrad

4.6k total citations · 1 hit paper
152 papers, 2.4k citations indexed

About

Jordan E. Axelrad is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Jordan E. Axelrad has authored 152 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Genetics, 87 papers in Epidemiology and 49 papers in Surgery. Recurrent topics in Jordan E. Axelrad's work include Inflammatory Bowel Disease (98 papers), Microscopic Colitis (73 papers) and Clostridium difficile and Clostridium perfringens research (21 papers). Jordan E. Axelrad is often cited by papers focused on Inflammatory Bowel Disease (98 papers), Microscopic Colitis (73 papers) and Clostridium difficile and Clostridium perfringens research (21 papers). Jordan E. Axelrad collaborates with scholars based in United States, Sweden and United Kingdom. Jordan E. Axelrad's co-authors include Simon Lichtiger, Vijay Yajnik, David Hudesman, Benjamin Lebwohl, Ken Cadwell, Shailja C. Shah, Jean‐Frédéric Colombel, Garrett Lawlor, Sam S. Chang and José U. Scher and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Investigation.

In The Last Decade

Jordan E. Axelrad

134 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment

2016 355 citations Jordan E. Axelrad et al. profile →

Peers

Countries citing papers authored by Jordan E. Axelrad

Since Specialization

Citations

This map shows the geographic impact of Jordan E. Axelrad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordan E. Axelrad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordan E. Axelrad more than expected).

Fields of papers citing papers by Jordan E. Axelrad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordan E. Axelrad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordan E. Axelrad. The network helps show where Jordan E. Axelrad may publish in the future.

Co-authorship network of co-authors of Jordan E. Axelrad

This figure shows the co-authorship network connecting the top 25 collaborators of Jordan E. Axelrad. A scholar is included among the top collaborators of Jordan E. Axelrad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordan E. Axelrad. Jordan E. Axelrad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of Risankizumab Dose Escalation Among Patients With Inflammatory Bowel Disease 2025 ·Inflammatory Bowel Diseases ·(unknown), Adam S. Faye, Jordan E. Axelrad	1
2	Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults with Inflammatory Bowel Disease 2025 ·Digestive Diseases and Sciences ·(unknown), Pakdee Rojanasopondist, (unknown), Cristina Fernández, (unknown), Alice Li, Nicole Werner, (unknown), Roberto Ortiz, Xinyu Wang, Megan E. Murphy, Jordan E. Axelrad, (unknown), Ariela Holmer, Sam S. Chang, David Hudesman, Seymour Katz, Lisa Malter, Adam S. Faye	0
3	Fecal Microbiota-based Therapies Compared to Fecal Microbiota Transplantation for Preventing Recurrent C. difficile Infection 2025 ·Clinical Gastroenterology and Hepatology ·(unknown), Paul Feuerstadt, Jessica R. Allegretti, Jordan E. Axelrad	0
4	Tofacitinib Uptake by Patient-Derived Intestinal Organoids Predicts Individual Clinical Responsiveness 2024 ·Gastroenterology ·Kyung Ku Jang, David Hudesman, Drew R. Jones, P’ng Loke, Jordan E. Axelrad, Ken Cadwell, (unknown), (unknown), Sakteesh Gurunathan, (unknown), Chaoting Zhou, (unknown)	7
5	Histologic Activity From Neoterminal Ileal Biopsies in Patients With Crohn's Disease in Endoscopic Remission is Associated With Postoperative Recurrence 2024 ·The American Journal of Gastroenterology ·Ravi S. Shah, (unknown), Salam Bachour, Abel Joseph, (unknown), (unknown), Adel Hajj Ali, Terry Li, (unknown), (unknown), (unknown), Miguel Regueiro, Jordan E. Axelrad, Edward L. Barnes, (unknown), Benjamin Click	0
6	246 COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN'S DISEASE. 2024 ·Gastroenterology ·(unknown), (unknown), Terry Li, Jordan E. Axelrad, Edward L. Barnes, (unknown), Miguel Regueiro, Frank I. Scott, Benjamin Click	0
7	S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes 2024 ·Journal of Clinical Investigation ·Dhaval Dixit, (unknown), (unknown), (unknown), Ken Cadwell, Jerry E. Chipuk, Jordan E. Axelrad, Susan R. Schwab	11
8	Mo1859 TREATMENT OUTCOMES OF PROLONGED INDUCTION OR REESCALATION DOSING OF UPADACITINIB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE 2024 ·Gastroenterology ·(unknown), (unknown), Adam S. Faye, Jordan E. Axelrad	1
9	Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry 2024 ·Clinical Gastroenterology and Hepatology ·Steven H. Itzkowitz, Yue Jiang, Cristina Villagra, Jean‐Frédéric Colombel, (unknown), Dana J. Lukin, David M. Faleck, Ellen Scherl, Shannon Chang, Lea Ann Chen, Seymour Katz, (unknown), Arun Swaminath, Francesca Petralia, (unknown), David B. Sachar, Lina Jandorf, Jordan E. Axelrad	5
10	Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s Disease 2023 ·Clinical Gastroenterology and Hepatology ·Ravi S. Shah, Salam Bachour, Abel Joseph, (unknown), Ruishen Lyu, (unknown), Terry Li, (unknown), (unknown), Adel Hajj Ali, (unknown), (unknown), Edward L. Barnes, Jordan E. Axelrad, Stefan D. Holubar, Miguel Regueiro, (unknown), Benjamin Click	5
11	Atherosclerosis as a Risk Factor of Inflammatory Bowel Disease: A Population-Based Case-Control Study 2023 ·The American Journal of Gastroenterology ·Adam S. Faye, Jordan E. Axelrad, Jiangwei Sun, Jonas Halfvarson, (unknown), Ola Olén, Jonas F. Ludvigsson	9
12	A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled Trial 2022 ·JMIR Research Protocols ·Jordan E. Axelrad, Millie D. Long, Sara Horst, Anita Afzali, Tamar Sapir, (unknown), (unknown), Robert S. Sandler, Raymond K. Cross	4
13	The γδ IEL effector API5 masks genetic susceptibility to Paneth cell death 2022 ·Nature ·Yu Matsuzawa, Xiaomin Yao, Akiko Koide, Beatrix Ueberheide, Jordan E. Axelrad, Bernardo Sgarbi Reis, Roham Parsa, Jessica A. Neil, Joseph C. Devlin, Eugene Rudensky, Md. Zahidunnabi Dewan, Michael Cammer, Richard S. Blumberg, Yi Ding, Kelly V. Ruggles, Daniel Mucida, Shohei Koide, Ken Cadwell	36
14	Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden 2020 ·Gut ·Jordan E. Axelrad, Ola Olén, Michael C. Sachs, Rune Erichsen, Lars Pedersen, Jonas Halfvarson, Johan Askling, Anders Ekbom, Henrik Toft Sørensen, Jonas F. Ludvigsson	36
15	Systematic review: gastrointestinal infection and incident inflammatory bowel disease 2020 ·Alimentary Pharmacology & Therapeutics ·Jordan E. Axelrad, Ken Cadwell, Jean‐Frédéric Colombel, Shailja C. Shah	41
16	Enteric tube placement in patients with esophageal varices: Risks and predictors of postinsertion gastrointestinal bleeding 2019 ·JGH Open ·(unknown), Ahmad Najdat Bazarbashi, Margot E. Cohen, (unknown), Yuxiu Lei, Jordan E. Axelrad, Alyson N. Fox, Subani Chandra, Fredric D. Gordon	12
17	Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance 2019 ·Clinical Gastroenterology and Hepatology ·(unknown), Shailja C. Shah, Joana Torres, Daniel Castañeda, (unknown), (unknown), Akash Kumar, Jordan E. Axelrad, Noam Harpaz, Thomas Ullman, Jean‐Frédéric Colombel, Bas Oldenburg, Steven H. Itzkowitz	24
18	Endoscopic Algorithm for Management of Gastrointestinal Bleeding in Patients With Continuous Flow LVADs: A Prospective Validation Study 2019 ·Journal of Cardiac Failure ·Jordan E. Axelrad, Adam S. Faye, A. Pinsino, Anusorn Thanataveerat, B. Cagliostro, (unknown), (unknown), R. Te-Frey, (unknown), A.R. Garan, Veli K. Topkara, Hiroo Takayama, Koji Takeda, Yoshifumi Naka, (unknown), Reuben Garcia-Carrasquillo, P.C. Colombo, Tamas A. Gonda, M. Yuzefpolskaya	6
19	Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio‐economic factors 2019 ·Alimentary Pharmacology & Therapeutics ·Manasi Agrawal, Shirley Cohen‐Mekelburg, Maia Kayal, Jordan E. Axelrad, (unknown), (unknown), Kanika Kamal, Adam S. Faye, (unknown), Ellen Scherl, Garrett Lawlor, Keith Sultan, Dana J. Lukin, Jean‐Frédéric Colombel, Ryan C. Ungaro	22
20	No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases 2018 ·Gastroenterology ·(unknown), Shailja C. Shah, Joren R. ten Hove, Joana Torres, Erik Mooiweer, Daniel Castañeda, (unknown), (unknown), Akash Kumar, Jordan E. Axelrad, Thomas Ullman, Jean‐Frédéric Colombel, Bas Oldenburg, Steven H. Itzkowitz	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact